Friedman David Matthew 4

What Happened
David Matthew Friedman, a member of Veradermics, Inc.'s (MANE) Board of Directors, was granted an award consisting of options covering 43,000 shares on February 3, 2026. The reported acquisition price is $0.00 (the grant cost to the recipient was zero); this is a derivative/options grant, not a purchase or sale of stock. The filing was submitted on February 5, 2026.

Key Details

• Transaction date: 2026-02-03; Filing date: 2026-02-05 (timely filing).
• Transaction type: Award/Grant of derivative securities (options) covering 43,000 shares; reported acquisition price $0.00.
• Shares owned after transaction: Not disclosed in this filing.
• Footnote summary:
  • F1: The options were awarded for board service but are being held by Mr. Friedman in his capacity as an employee of Suvretta Capital Management, LLC for the benefit of funds managed by Suvretta (Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd.). Mr. Friedman disclaims beneficial ownership; the Funds/Suvretta may have an indirect pecuniary interest.
  • F2: The options will be fully vested and exercisable on February 3, 2027 (one-year cliff).

Context
This filing reports an option award (a derivative grant) rather than an outright stock purchase or sale. Because Mr. Friedman disclaims beneficial ownership and the options are held for the benefit of institutional funds managed by Suvretta Capital, this transaction reflects director compensation routed to an investment manager/funds rather than personal insider buying. The options vest in one year; there is no indication of an immediate exercise or sale.